Literature DB >> 22995029

Intravitreal triamcinolone versus intravitreal bevacizumab in the treatment of exudative retinal detachment secondary to posterior uveal melanoma.

Raffaele Parrozzani1, Elisabetta Pilotto, Alessia Dario, Giacomo Miglionico, Edoardo Midena.   

Abstract

PURPOSE: To evaluate the efficacy and safety of prompt intravitreal triamcinolone acetonide injection (4 mg/0.1 mL) vs intravitreal bevacizumab injection (1.25 mg/0.05 mL) compared with observation in the management of extensive exudative retinal detachment secondary to posterior uveal melanoma.
DESIGN: Retrospective, nonrandomized, interventional case series.
METHODS: setting: Institutional. patients: Ninety-six patients affected by posterior uveal melanoma with large exudative retinal detachment (>10 mm in largest basal diameter) were included. intervention: Patients received intravitreal triamcinolone acetonide (32 eyes) or intravitreal bevacizumab (32 eyes) at plaque removal. Thirty-two patients served as controls (observation group). All groups were matched for age, sex, initial tumor thickness and largest basal diameter, largest exudative retinal detachment basal diameter, tumor location, and Bruch membrane rupture. Patients underwent monthly follow-up examinations in the first 6 months and every 3 months thereafter. Follow-up was longer than 24 months. main outcome measure: Exudative retinal detachment resolution (B-scan ultrasonography), steroid-induced cataract, steroid-induced increased IOP.
RESULTS: Follow-up was 37 ± 7 months. Marked exudative retinal detachment regression was documented in 22 (69%) intravitreal triamcinolone acetonide-treated vs 11 (34%) intravitreal bevacizumab-treated and 9 (28%) untreated eyes (P = .0007 and P = .0001, respectively). No statistical significance was found between intravitreal bevacizumab group vs observation group (P = .45) Steroid-induced cataract was observed in 4 intravitreal triamcinolone acetonide-treated patients (12%). Neither steroid-induced increased IOP nor other short- or long-term side effects were documented.
CONCLUSION: Intraoperative intravitreal triamcinolone acetonide injection induces earlier and marked exudative retinal detachment resolution after brachytherapy of posterior uveal melanoma. Risk and benefit should be balanced vs steroid-induced cataract.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22995029     DOI: 10.1016/j.ajo.2012.06.026

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

1.  Endodrainage, Tumor Photocoagulation, and Silicone Oil Tamponade for Primary Exudative Retinal Detachment due to Choroidal Melanoma Persisting after Proton Beam Therapy.

Authors:  Ira Seibel; Dino Cordini; Gregor Willerding; Aline Isabel Riechardt; Antonia Maria Joussen
Journal:  Ocul Oncol Pathol       Date:  2014-07-22

2.  Case Report: GNAQ- and SF3B1 Mutations in an Aggressive Case of Relapsing Uveal Ring Melanoma.

Authors:  Michelle Prasuhn; Josephine Christin Freitag; Sabine Lüken; Vinodh Kakkassery; Hartmut Merz; Almuth Caliebe; Malte Spielmann; Mahdy Ranjbar; Felix Rommel
Journal:  Front Oncol       Date:  2022-05-25       Impact factor: 5.738

3.  Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy.

Authors:  Amir Mahdjoubi; Marie Najean; Stéphanie Lemaitre; Sylvain Dureau; Rémi Dendale; Christine Levy; Livia Lumbroso-Le Rouic; Laurence Desjardins; Nathalie Cassoux
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-11-07       Impact factor: 3.117

Review 4.  Effects of radiotherapy on uveal melanomas and adjacent tissues.

Authors:  C Groenewald; L Konstantinidis; B Damato
Journal:  Eye (Lond)       Date:  2012-11-30       Impact factor: 3.775

Review 5.  Non-Cancer Effects following Ionizing Irradiation Involving the Eye and Orbit.

Authors:  Juliette Thariat; Arnaud Martel; Alexandre Matet; Olivier Loria; Laurent Kodjikian; Anh-Minh Nguyen; Laurence Rosier; Joël Herault; Sacha Nahon-Estève; Thibaud Mathis
Journal:  Cancers (Basel)       Date:  2022-02-25       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.